Abstract
The pyrimidine analog 5-fluorouracil (5FU) has been used in the treatment against several solid carcinomas, mainly of the colon, for several decades (1). However, overall response rate is only about 20%, while gastrointestinal and myeloid toxicity are dose-limiting (1). Research on 5FU has been directed towards enhancing 5FU anabolism by combination with e.g. methotrexate (2) or thymidine (3) and towards the development of several analogs of 5FU. One recent analog, Doxifluridine (5′-deoxy-5-fluorouridine, 5’dFUR) showed an improved therapeutic index against a broad range of murine and rat tumors (4,5) and therapeutic activity in human advanced rectosigmoid adenocarcinoma (6).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
B.A. Chabner, Pyrimidine antagonists, in: Pharmacologic principles of cancer treatment, B.A. Chabner, ed., pp. 183–212, Saunders, Philadelphia (1982).
E. Mim and J.R. Bertino, Chemotherapia II: 147–162 (1985).
C.W. Young, T.M. Woodcock and D.S. Martin, Cancer Treatm. Rep., 65, (suppl. 3): 83–87 (1981).
W. Bollag, H.R. Hartmann, Eur. J. Cancer, 16: 427–432 (1980).
R.D. Armstrong and R.B. Diasio, Cancer Res. 40: 3333–3338 (1980).
R. Abele, P. Alberto, S. Kaplan, P. Siegenthaler, V. Hoffman, H.J. Ryssel, D. Hartman, E.E. Holdener and F. Cavalli, J. Clin. Oncol. 1: 750–754 (1983).
D.S. Martin, R.L. StolfiL, S.C. Sawyer, S. Spiegelman and C.W. Young, Cancer Res. 42: 3964–3970 (1982).
P. Klubes, I. Cerna and M.A. Meldon, Cancer Chemother. Pharmacol. 8: 17–21 (1982).
P. Klubes and I. Cerna, Cancer Res. 43: 3182–3186 (1983).
T.H. Corbett, D.P. Griswold, B.J. Roberts, J.C. Peckham and F.M. Schabel, Cancer Res. 35: 2434–2439 (1975).
E. Boven, W.J.F. van der Vijgh, M.M. Nauta, H.M.M. Schlüper and H.M. Pinedo, Cancer Res. 45: 86–90 (1985).
P.J. van Kranenburg-Voogd, H.J. Keizer and L.M. van Putten, Eur. J. Cancer 14 (suppl.): 153–157 (1978).
T.H. Corbett, D.P. Griswold, B.J. Roberts, J.C. Peckham and F.M. Schabel, Cancer 40: 2660–2690 (1977).
E.A. de Bruyn, A.T. van Oosterom, U.R. Tjaden, H.J.E.M. van Reeuwijk and H.M. Pinedo, Cancer Res. in press (1985).
A.M. Yeager, J. Levin and F.C. Levin, Exp. Hematol. 11: 944–952 (1983).
J.W. Darnofsky and R.E. Handschumacher, submitted (1985).
C.J. van Groeningen, A. Leyva, G.J. Peters, I. Kraal and H.M. Pinedo, Proc. AACR 35: 169 (abstract 670) (1984).
A. Leyva, C.J. van Groeningen, I. Kraal, H. Gall, G.J. Peters, J. Lankelma and H.M. Pinedo, Cancer Res. 44: 5928–5933 (1984).
C.J. van Groeningen, A. Leyva, I. Kraal, G.J. Peters and H.M. Pinedo, submitted (1985).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Press, New York
About this chapter
Cite this chapter
Peters, G.J. et al. (1986). Toxicity and Antitumor Effect of 5-Fluorouracil and its Rescue by Uridine. In: Nyhan, W.L., Thompson, L.F., Watts, R.W.E. (eds) Purine and Pyrimidine Metabolism in Man V. Advances in Experimental Medicine and Biology, vol 195B. Springer, New York, NY. https://doi.org/10.1007/978-1-4684-1248-2_19
Download citation
DOI: https://doi.org/10.1007/978-1-4684-1248-2_19
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4684-1250-5
Online ISBN: 978-1-4684-1248-2
eBook Packages: Springer Book Archive